This article refers to:
In the article, “Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region,” by Vrdoljak, Ciuleanu, Kharkevich et al. (Expert Opin. Pharmocother 2012:13(02):159-74), some errors were identified. In table six, under the column Bevacizumab, in the row for Czech Republic, “100% reimbursed” should read, “100% reimbursed (reimbursed only from hospital fixed budget),” and under the column Everolimus, in the row for Czech Republic, “100% reimbursed as a second line in a specific program” should read, “100% reimbursed as a second line.”
Informa Healthcare apologises for any confusion caused.